Cardiol Therapeutics (CRDL) Payables (2020 - 2026)

Cardiol Therapeutics' Payables history runs 7 years deep, the most recent figure standing at $5.2 million for Q1 2026.

• Quarterly Payables fell 3.9% year-over-year to $5.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.2 million (down 3.9% YoY) and the FY2025 annual result came in at $4.0 million, down 19.35% from the prior year.
• Payables was $5.2 million for Q1 2026 at Cardiol Therapeutics, up from $4.0 million in the prior quarter.
• Across five years, Payables topped out at $8.9 million in Q2 2022 and bottomed at $2.4 million in Q3 2025.
• A 5-year average of $6.1 million and a median of $6.0 million in 2023 frame the typical range for Payables.
• Annual changes were most pronounced in 2022 — Payables surged 279.53% — and 2025, when it plunged 53.42%.
• Cardiol Therapeutics' Payables stood at $7.2 million in 2022, then fell by 15.37% to $6.1 million in 2023, then retreated by 17.88% to $5.0 million in 2024, then fell by 19.35% to $4.0 million in 2025, then gained by 28.31% to $5.2 million in 2026.
• Business Quant data shows CRDL's Payables at $5.2 million in Q1 2026, $4.0 million in Q4 2025, and $2.4 million in Q3 2025.